insights_auto
Sebab LONA menurun 3.99%?
Terokai Dengan Lebih Terperincichevron_right
LONA:NASDAQ
LeonaBio Inc
USD 2.65
arrow_downward
-3.99%(-0.11) 1H
USD 2.55
arrow_downward
-3.77% (-0.10)bedtimeSelepas waktu pejabat
Ditutup: 18 Nov, 4:00:01 PTG GMT-5 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk LONA...
Buka
USD 2.77
Tinggi
USD 3.05
Rendah
USD 2.51
Permodalan Pasaran
34.65J
Purata volum
77.64K
Volum
44.50K
tgi 52 mgu
USD 14.19
rdh 52 mgu
USD 2.21
EPS
-USD 19.72
Beta
1.91
Syer tertunggak
13.08J
Bilangan pekerja
19
Buka
USD 2.77
Tinggi
USD 3.05
Rendah
USD 2.51
Permodalan Pasaran
34.65J
Purata volum
77.64K
Volum
44.50K
tgi 52 mgu
USD 14.19
rdh 52 mgu
USD 2.21
EPS
-USD 19.72
Beta
1.91
Syer tertunggak
13.08J
Bilangan pekerja
19
Cerita berita
Daripada sumber web dan rakan kongsi berita
Investing.com Canada
·
8 jam lalu
Mizuho cuts LeonaBio stock price target on financing concerns By Investing.com
Investing.com
·
1 hari lalu
Citizens cuts LeonaBio stock price target to $16 on valuation
www.tokenpost.com
·
2 hari lalu
LeonaBio Posts $0.89 Q3 GAAP Loss Per Share, Missing Estimates by 20 Cents
scanx.trade
·
2 hari lalu
LeonaBio Q3 Results: Loss widens 47% YoY to $(0.89) per share
Profil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Perihal LeonaBio Inc
CEO-
Pekerja19
Diasaskan2011
Ibu pejabatBothell, Washington, Amerika Syarikat
SektorHealth Care
Industri-
Laman webleonabio.com